Side-by-side comparison of AI visibility scores, market position, and capabilities
Jericho NY open-air grocery-anchored shopping centers (NYSE: KIM) ~$2.1B FY2024 revenue; 570+ centers in top-20 metros, RPT acquisition 2023, Last Mile mixed-use strategy competing with Regency Centers.
Kimco Realty Corporation is a Jericho, New York-based open-air shopping center REIT — publicly traded on the New York Stock Exchange (NYSE: KIM) as an S&P 500 Real Estate component — owning, operating, and developing open-air grocery-anchored and mixed-use shopping centers primarily in the top-20 major metropolitan markets (New York metro, Los Angeles, Miami, Chicago, Philadelphia, Washington DC, Atlanta, San Francisco Bay Area) through approximately 2,000 employees. Kimco Realty owns 570+ open-air shopping centers aggregating 100 million+ square feet of gross leasable area (GLA), with the portfolio anchored by necessity-based tenants (grocery stores, home improvement, pharmacy, discount retail) that generate traffic-driving anchor tenancy for inline small shop tenants. In January 2023, Kimco Realty completed the acquisition of RPT Realty (NYSE: RPT — a Michigan-based open-air shopping center REIT owning 57 shopping centers) for $2.0 billion — expanding Kimco's footprint in Sunbelt markets (Tampa, Orlando, Atlanta, Charlotte) and adding RPT's grocery-anchored portfolio to Kimco's predominantly major-metro coastal centers. CEO Conor Flynn has executed Kimco's "Last Mile" real estate strategy: concentrating the portfolio in high-density urban and first-ring suburban markets where open-air shopping centers serve as the last-mile convenience fulfillment point for consumers combining physical shopping with BOPIS (buy online, pick up in store) — positioning Kimco's shopping centers as logistics infrastructure for omnichannel retail rather than purely experiential retail destinations.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.